bexarotene has been researched along with Carcinoma, Non-Small Cell Lung in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 16 (64.00) | 29.6817 |
| 2010's | 9 (36.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ai, X; Lu, S; Mao, F; Shen, S; Shentu, Y; Wang, J | 1 |
| Chhatwani, L; Jacobs, CD; Lopez-Anaya, A; Padda, SK; Wakelee, HA; Zhou, L | 1 |
| Friedrich, MJ | 1 |
| Busch, AM; Cyrus, J; Dmitrovsky, E; Dragnev, KH; Erkmen, CP; Freemantle, SJ; Galimberti, F; Johnstone, D; Kurie, JM; Liu, X; Ma, T; Memoli, V; Nugent, W; Rigas, JR; Seltzer, M; Tsongalis, GJ; Waxman, S | 1 |
| Dziewanowska, ZE; Hermann, TW; Luo, W; Malo, N; Marschke, KB; Meglasson, MD; Negro-Vilar, A; Ng, SC; Sanders, JM; Schork, NJ; Tooker, P; Zapala, MA; Zhang, J | 1 |
| Chu, Q; Jacobs, CD; Lopez-Anaya, A; Rodon, J; Rowinsky, EK; Takimoto, CH; Wakelee, HA | 1 |
| Chu, Q; Dunlop, D; Hao, D; Jacobs, CD; Leighl, N; Lopez-Anaya, A; Middleton, G; Ramlau, R; Rodon, J; Rowinsky, EK; Takimoto, CH; Wakelee, HA; Zatloukal, P | 1 |
| Dunlop, D; Hao, D; Jacobs, CD; Leighl, N; Lopez-Anaya, A; Middleton, G; Ramlau, R; Wakelee, HA; Zatloukal, P | 1 |
| Alden, C; Blumenschein, G; Davis, SE; Herbst, R; Hong, WK; Kim, E; Lee, JJ; Lippman, S; Liu, S; Stewart, D; Tang, XM; Tsao, AS; Wistuba, I | 1 |
| Bissonnette, RP; Cooke, TA; Corpuz, MR; Lamph, WW; Negro-Vilar, A; Prudente, RY; Yen, WC | 1 |
| Dragnev, KH; Rigas, JR | 1 |
| Dmitrovsky, E; Dragnev, KH; Ma, Y; Petty, WJ; Rigas, JR | 1 |
| Bissonnette, RP; Fan, B; Hermann, TW; Lamph, WW; Negro-Vilar, A; Roegner, K; Tooker, P; Yen, WC | 1 |
| Tyagi, P | 1 |
| Bedor, M; Bisaccia, S; Doyle, LA; Edelman, MJ; Hausner, P; Kalra, K; Kendall, J; Smith, R | 1 |
| Jia, D; Lubet, RA; Wang, D; Wang, Y; Yao, R; You, M; Zhang, Z | 1 |
| Biddle, A; Desai, NB; Dmitrovsky, E; Dragnev, KH; Memoli, V; Petty, WJ; Rigas, JR; Shah, S | 1 |
| Nandan, R | 1 |
| Chen, X; Ding, Y; Fu, J; Huang, D; Li, H | 1 |
| Bolejack, V; Crowley, J; Ekstrand, B; Ghalie, R; Govindan, R; Jaunakais, D; Kennedy, P; Sandler, A; Schwartzberg, L; Williams, C | 1 |
| Black, CC; Dmitrovsky, E; Dragnev, KH; Hermann, T; Lewis, LD; Memoli, V; Negro-Vilar, A; Nugent, WC; Petty, WJ; Rigas, JR; Shah, SJ | 1 |
| Hermann, TW; Negro-Vilar, A; Ng, SC; Tooker, P; Yen, WC | 1 |
| Blumenschein, GR; Dziewanowska, ZE; Gatzemeier, U; Jotte, RM; Khuri, FR; Le Treut, J; Miller, WH; Negro-Vilar, A; Sun, SL; von Pawel, J; Zhang, JK | 1 |
| Dziewanowska, ZE; Gottfried, M; Jassem, J; Negro-Vilar, A; Negro-Vilar, R; Orlov, SV; Pereira, JR; Rahal, S; Ramlau, R; Schwarzenberger, P; Temperley, G; Zatloukal, P; Zhang, JK | 1 |
| Figlin, RA; Fox, N; Gralla, RJ; Hong, WK; Huyghe, MR; Kean, Y; Khuri, FR; Munden, R; Reich, SD; Rigas, JR; Shin, DM | 1 |
2 review(s) available for bexarotene and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene.
Topics: Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Carcinoma, Non-Small-Cell Lung; Cell Division; Cell Proliferation; Clinical Trials as Topic; Humans; Lung Neoplasms; Tetrahydronaphthalenes; Treatment Outcome | 2005 |
Nonclassical retinoids and lung carcinogenesis.
Topics: Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Carcinoma, Non-Small-Cell Lung; Cyclins; ErbB Receptors; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Receptors, Retinoic Acid; Retinoids; Tetrahydronaphthalenes; Ubiquitin | 2005 |
14 trial(s) available for bexarotene and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Phase I and pharmacokinetic study of bexarotene in combination with gefitinib in the third-line treatment of non-small-cell lung cancer: brief report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Tetrahydronaphthalenes; Treatment Outcome | 2013 |
Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models.
Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cyclin D1; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunoblotting; Immunoenzyme Techniques; Lung Neoplasms; Male; Mice; Mice, Transgenic; Middle Aged; Mouth Mucosa; Mutation; Necrosis; Neoplasm Recurrence, Local; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Salvage Therapy; Survival Rate; Tetrahydronaphthalenes; Treatment Outcome; Tumor Cells, Cultured | 2011 |
A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC).
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Humans; Hypolipidemic Agents; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Retinoid X Receptors; Tetrahydronaphthalenes | 2012 |
The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Atorvastatin; Bexarotene; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Interactions; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertriglyceridemia; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Pyrroles; Tetrahydronaphthalenes; Treatment Outcome | 2012 |
A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC).
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Humans; Hypolipidemic Agents; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Retinoid X Receptors; Tetrahydronaphthalenes; Vinblastine; Vinorelbine | 2012 |
Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Piperidines; Prognosis; Quinazolines; Retrospective Studies; Salvage Therapy; Sorafenib; Survival Rate; Tetrahydronaphthalenes | 2012 |
Bexarotene in combination with chemotherapy fails to prolong survival in patients with advanced non-small-cell lung cancer: results from the SPIRIT I and II trials.
Topics: Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Tetrahydronaphthalenes; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Phase II trial of the novel retinoid, bexarotene, and gemcitabine plus carboplatin in advanced non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bexarotene; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Hypertriglyceridemia; Lung Neoplasms; Male; Middle Aged; Survival Rate; Tetrahydronaphthalenes; Treatment Outcome | 2005 |
Bexarotene and erlotinib for aerodigestive tract cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cell Survival; Cyclin D1; Digestive System Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Head and Neck Neoplasms; Humans; Hypertriglyceridemia; Lung Neoplasms; Male; Middle Aged; Mouth Mucosa; Protein Kinase Inhibitors; Quinazolines; Sequence Analysis, DNA; Tetrahydronaphthalenes; Treatment Outcome; Tumor Cells, Cultured | 2005 |
Phase II trial of bexarotene capsules in patients with advanced non-small-cell lung cancer after failure of two or more previous therapies.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticarcinogenic Agents; Bexarotene; Capsules; Carcinoma, Non-Small-Cell Lung; Exanthema; Female; Humans; Hypertriglyceridemia; Lung Neoplasms; Male; Middle Aged; Pleural Effusion; Survival Analysis; Tetrahydronaphthalenes | 2006 |
A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer.
Topics: Antineoplastic Agents; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Pilot Projects; Postoperative Period; Premedication; Tetrahydronaphthalenes; Tumor Cells, Cultured | 2007 |
Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Humans; Hypertriglyceridemia; Lung Neoplasms; Male; Middle Aged; Neoplasm Transplantation; Paclitaxel; Survival Analysis; Tetrahydronaphthalenes | 2008 |
Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Female; Humans; Hypertriglyceridemia; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Survival Rate; Tetrahydronaphthalenes; Triglycerides; Vinblastine; Vinorelbine | 2008 |
Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Female; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Tetrahydronaphthalenes; Vinblastine; Vinorelbine | 2001 |
9 other study(ies) available for bexarotene and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Bexarotene inhibits the viability of non-small cell lung cancer cells via slc10a2/PPARĪ³/PTEN/mTOR signaling pathway.
Topics: Apoptosis; Bexarotene; Biomarkers; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Gene Expression; Humans; Lung Neoplasms; Organic Anion Transporters, Sodium-Dependent; PPAR gamma; PTEN Phosphohydrolase; Signal Transduction; Symporters; TOR Serine-Threonine Kinases | 2018 |
NSCLC drug targets acquire new visibility.
Topics: Antineoplastic Agents; Benzenesulfonates; Benzimidazoles; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Niacinamide; Oncogene Proteins, Fusion; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Sorafenib; Tetrahydronaphthalenes; Treatment Outcome | 2011 |
Identification of polymorphisms associated with hypertriglyceridemia and prolonged survival induced by bexarotene in treating non-small cell lung cancer.
Topics: Bexarotene; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Clinical Trials, Phase III as Topic; DNA; Female; Genetic Predisposition to Disease; Humans; Hypertriglyceridemia; Lung Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Tetrahydronaphthalenes | 2011 |
A selective retinoid X receptor agonist bexarotene (Targretin) prevents and overcomes acquired paclitaxel (Taxol) resistance in human non-small cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bexarotene; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Mutation; Paclitaxel; Retinoid X Receptors; Survival Rate; Tetrahydronaphthalenes; Transplantation, Heterologous; Tumor Cells, Cultured | 2004 |
The retinoid X receptor agonist bexarotene (Targretin) synergistically enhances the growth inhibitory activity of cytotoxic drugs in non-small cell lung cancer cells.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Phytogenic; Bexarotene; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Interactions; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Paclitaxel; Tetrahydronaphthalenes; Transplantation, Heterologous; Vinblastine; Vinorelbine | 2005 |
Prevention of lung cancer progression by bexarotene in mouse models.
Topics: Adenocarcinoma; Adenoma; Animals; Anticarcinogenic Agents; Bexarotene; Carcinogens; Carcinoma, Non-Small-Cell Lung; Disease Models, Animal; Disease Progression; Genes, p53; Genes, ras; Humans; Lung Neoplasms; Mice; Mice, Transgenic; Tetrahydronaphthalenes; Urethane | 2006 |
Promising results achieved with a combination of chemotherapy and two retinoids in patients with advanced non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Biological Availability; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate; Tetrahydronaphthalenes; Treatment Outcome; Tretinoin | 2006 |
The retinoid X receptor-selective ligand, LGD1069, inhibits tumor-induced angiogenesis via suppression of VEGF in human non-small cell lung cancer.
Topics: Animals; Anticarcinogenic Agents; Bexarotene; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dose-Response Relationship, Drug; Enzyme Activation; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; Immunohistochemistry; JNK Mitogen-Activated Protein Kinases; Lung Neoplasms; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neovascularization, Pathologic; Platelet Endothelial Cell Adhesion Molecule-1; Retinoid X Receptors; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tetrahydronaphthalenes; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2007 |
Bexarotene (LGD1069, Targretin), a selective retinoid X receptor agonist, prevents and reverses gemcitabine resistance in NSCLC cells by modulating gene amplification.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Gene Amplification; Humans; Lung Neoplasms; Mice; Mice, Nude; Retinoid X Receptors; Tetrahydronaphthalenes; Xenograft Model Antitumor Assays | 2007 |